PET/CT brain scans of the enzyme aromatase could help providers pinpoint which patients will struggle with obesity and self-regulation.
PET scans can be a crystal ball, helping providers predict whether men and women will struggle with obesity and poor self-regulation.
These images of the amygdala shed light on the relationship between aromatase, an enzyme associated with the production and processing of estrogen, and higher body mass index (BMI) and diminished self-control. A team of investigators from Stony Brook University shared their discovery in an article published on Aug. 31 in PNAS.
According to their analysis, the team’s findings indicate that imaging aromatase in the brain could be a unique way to characterize the role estrogen plays in obesity and other conditions where self-regulation can be impaired.
To test how estrogen influences body weight and stimuli-induced behavior, the researchers, led by Anat Beigon, Ph.D. professor of radiology and Director of the Center on Gender, Hormones, and Health at Stonybrook’s Renaissance School of Medicine, used an aromatase-specific radiotracer with PET imaging to measure levels of the enzyme in the brains of 43 men and women. Participants were in the healthy to obese weight ranges. Their average age was 40 years, and their average BMI was 28.
“This is the first study to show a direct correlation between aromatase availability in the amygdala and BMI,” Beigon said. “It is also the first to how an inverse correlation between amygdala aromatase and self-control in the same individuals.”
Based on their regression model analysis that controlled for both sex and age, she said, amygdala aromatase affected men and women similarly. Consequently, it has the potential to be a sex neutral contributor to BMI, making it a possible measurable marker for both men and women who struggle with obesity and self-regulation.
Further work is needed to fully understand the role of estrogen, however, she said. The next step is to examine other brain regions where estrogen is shown to influence appetite and energy use. These investigations could determine how valuable aromatase measurements are in discriminating between binge eating and healthy populations, as well as predicting whether a patient will regain wait after bariatric surgery.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
2 Commerce Drive
Cranbury, NJ 08512